{"title":"The Double-Edged Sword of Genomic DNA Methylation: Orchestrating Gastric Carcinogenesis and Shaping Precision Oncology.","authors":"Xuan Chen, Chao Luo, Wei Wen","doi":"10.32604/or.2026.079753","DOIUrl":null,"url":null,"abstract":"<p><p>This article systematically elaborates on the dual role of DNA methylation in the initiation and progression of gastric cancer and its potential clinical applications in precision oncology. As a core epigenetic mechanism, DNA methylation drives the multistage development of gastric cancer through the coordinated dysregulation of genome-wide hypomethylation and promoter-specific hypermethylation, playing a key role in chronic inflammation and epigenetic reprogramming, particularly in the context of <i>Helicobacter pylori</i> infection. The article focuses on analyzing the central pathogenic mechanisms of DNA methylation, including the silencing of tumor suppressor genes, induction of genomic instability, promotion of the CpG island methylator phenotype, and facilitation of epithelial-mesenchymal transition. It further explores the clinical utility of DNA methylation as a biomarker for early diagnosis, prognosis evaluation, recurrence monitoring, and prediction of therapeutic response in gastric cancer. Moreover, the article reviews epigenetic therapeutic strategies represented by hypomethylating agents and their potential and challenges when combined with chemotherapy or immunotherapy, envisioning an integrated precision medicine model based on methylation profiling.</p>","PeriodicalId":19537,"journal":{"name":"Oncology Research","volume":"34 9","pages":"3"},"PeriodicalIF":4.6000,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13494473/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.32604/or.2026.079753","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
This article systematically elaborates on the dual role of DNA methylation in the initiation and progression of gastric cancer and its potential clinical applications in precision oncology. As a core epigenetic mechanism, DNA methylation drives the multistage development of gastric cancer through the coordinated dysregulation of genome-wide hypomethylation and promoter-specific hypermethylation, playing a key role in chronic inflammation and epigenetic reprogramming, particularly in the context of Helicobacter pylori infection. The article focuses on analyzing the central pathogenic mechanisms of DNA methylation, including the silencing of tumor suppressor genes, induction of genomic instability, promotion of the CpG island methylator phenotype, and facilitation of epithelial-mesenchymal transition. It further explores the clinical utility of DNA methylation as a biomarker for early diagnosis, prognosis evaluation, recurrence monitoring, and prediction of therapeutic response in gastric cancer. Moreover, the article reviews epigenetic therapeutic strategies represented by hypomethylating agents and their potential and challenges when combined with chemotherapy or immunotherapy, envisioning an integrated precision medicine model based on methylation profiling.
期刊介绍：
Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
